Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide - sprookjes - yvandenbroek - TriplyDB

Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide

Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide

http://www.wikidata.org/entity/Q26749476

about

Marine Sponge Natural Products with Anticancer Potential: An Updated Review.Cutaneous angiosarcoma: update on biology and latest treatment.Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY).

P2860

Q43245354-363F5AAF-40CF-4C9A-8C62-205E565AC911 Q47807442-F71EF26C-C96F-415C-8B0F-C2C09DB8049C Q50045537-9BABE72B-00F2-4970-A026-EE9F597439FB

P2860

Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide

http://www.wikidata.org/entity/Q26749476

description

2016 nî lūn-bûn

@nan

2016 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի մարտին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide

@ast

Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide

@en

Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide

@nl

type

label

Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide

@ast

Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide

@en

Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide

@nl

prefLabel

Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide

@ast

Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide

@en

Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide

@nl

P1433

Q26749476-31D93E0E-084C-46AB-A5C4-7F781611C348

P1476

Q26749476-6553FB82-596F-4B3C-A7E9-1DF3F29CB3C7

P2093

Q26749476-132629A4-3BDA-49D2-8D15-298175A9BC57

Q26749476-3FD281FF-BB4D-4BEC-BB35-15A789C0E9BE

Q26749476-5DB94469-6C66-43BD-9309-E3BCF8573D6F

Q26749476-7E3006E5-CF1F-4F71-B01D-823B1A1A0C83

Q26749476-928C51B2-FC1B-424F-A2AB-05CD78D4909D

Q26749476-9E0D4F3F-9BF1-4B66-B9DA-9B36F34CE11E

Q26749476-DE435300-09D4-4FD0-A433-2B245A3D4BE8

P2860

Q26749476-00574013-82FF-4935-809D-1408602AEB76

Q26749476-047BA9F6-3467-4E22-88B2-75D1CC9E97B9

Q26749476-05123278-02B7-49C3-9516-6FF24A978DA4

Q26749476-228D03EE-72B7-46A7-BD6F-A23C4FF0A065

Q26749476-32AFA9FA-822C-4F3B-A53F-AC68D522D36E

Q26749476-33D766B1-2942-4600-9A5D-0448F02AECB5

Q26749476-373C042D-BBF8-43C1-907F-AB82C29E7C1F

Q26749476-3849C196-051F-469A-8751-DFFDDBDA06AD

Q26749476-3B13DDFF-F153-4426-A0B6-3935DFCF39FA

Q26749476-3EA12E64-3FCB-48DC-A22C-59FDFB66C16F

P304

Q26749476-CCC0C279-B21C-4430-8D7A-A1CF905C5DC3

P31

Q26749476-E434E625-221B-4115-96A1-9C16843791D5

P3181

Q26749476-56990BE8-A136-4588-91A3-9AA919E69E22

P356

Q26749476-FFD3A05A-2ECC-4A55-8C7F-31724DB2463A

P407

Q26749476-E71A9D98-A393-485B-B083-16BADE4CE682

P433

Q26749476-667C1593-9305-4937-B854-F5B24935F7AA

P478

Q26749476-9AD08AB3-6D2F-4518-A652-A0C4B3C1BC46

P50

Q26749476-8D902F8C-7B6B-4B8C-8D94-A04C290EDB26

P577

Q26749476-995C6868-21EE-4A2F-8708-904E1B572F31

P5875

Q26749476-6F22BA5A-6B35-4F22-8864-37D370D22D60

P698

Q26749476-90C12812-C8EE-4063-AEDB-833E75831E5F

P932

Q26749476-3B12AB09-3E45-436D-94D0-BBCC5D025114

P3181

P356

JBC.2016.19.1.8

P1433

Journal of breast cancer

P1476

Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide

@en

P2093

Antonio Villalon

http://www.w3.org/2001/XMLSchema#string

Asian Working Group for Eribulin Clinical Guide

http://www.w3.org/2001/XMLSchema#string

B K Smruti

http://www.w3.org/2001/XMLSchema#string

Fiona Tsui-Fen Cheng

http://www.w3.org/2001/XMLSchema#string

Janice Tsang

http://www.w3.org/2001/XMLSchema#string

Jungsil Ro

http://www.w3.org/2001/XMLSchema#string

Virote Sriuranpong

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase

In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B

Neurologic complications of chemotherapy agents

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†

Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

Impact of modern chemotherapy on the survival of women presenting with de novo metastatic breast cancer.

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.

Is breast cancer survival improving?

P304

8-17

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

5046381

http://www.w3.org/2001/XMLSchema#string

P356

10.4048/JBC.2016.19.1.8

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

299529202

http://www.w3.org/2001/XMLSchema#string

P698

27066091

http://www.w3.org/2001/XMLSchema#string

P932

4822111

http://www.w3.org/2001/XMLSchema#string